Outlook Therapeutics, Inc. quarterly report, Q1 FY2017

Business context and reporting period

The filing is for the three months ended December 31, 2016, the first quarter of fiscal 2017. Important entity note: although the request identifies Outlook Therapeutics, Inc., the filing itself names the registrant as Oncobiologics, Inc. (now associated with the Outlook Therapeutics name); investors should confirm the filing and entity match.

Oncobiologics was a clinical-stage biosimilar developer with no approved products or product-sales revenue. Its lead candidates were ONS-3010, a Humira biosimilar, and ONS-1045, an Avastin biosimilar; both had completed Phase 1 trials. The company reported preparations for Phase 3 development, contingent on funding.

Financial performance and position

Amounts are U.S. dollars; comparisons are with the three months ended December 31, 2015.

There was no product-sales gross margin to report. Collaboration revenue came from licensing arrangements and deferred-revenue recognition; the filing states that the revenue decline reflected fewer milestone payments and a longer estimated performance period. Operating expenses rose about 5%, while net loss widened about 13%. Operating cash use was lower year over year, principally due to working-capital movements and noncash items, including increased accounts payable—not evidence of positive operating cash generation.

At December 31, 2016, current assets were $3.175 million and current liabilities were $32.129 million, a working-capital deficit of approximately $28.955 million. Total liabilities were $42.278 million, total assets $20.446 million, and stockholders’ deficit $21.832 million. The company reported an accumulated deficit of $166.492 million.

In December 2016, the company issued $8.35 million principal amount of senior secured notes, bearing 5% interest and due December 22, 2017; the balance sheet carried them at $4.934 million net of debt discount. The notes are secured by company assets and intellectual property and were issued with warrants. The company also had $4.613 million of stockholder notes payable on demand. Capital lease obligations were $1.128 million in total. A $4.129 million warrant liability was recorded, including a $0.810 million fair-value expense for the quarter.

Material changes, outlook, and risks

• Revenue fell from $0.995 million to $0.303 million; no milestone payments were recognized in the current quarter, versus $0.500 million in the prior-year quarter. The company also extended its estimated collaboration performance period from December 2019 to December 2021.
• R&D expense increased by $0.578 million, primarily from higher clinical and preclinical development costs, including Phase 3 preparation for ONS-3010, and increased headcount. G&A increased by $0.215 million, with higher stock-based compensation and facilities costs partly offset by lower professional fees.
• Financing included the December note-and-warrant issuance; proceeds were partly used to repay $2.4 million of senior bank loans. In January 2017, the company received a further $1.65 million from issuance of notes and warrants.
• Management said cash on hand at December 31 plus the January proceeds was expected to fund operations only through February 2017. Substantial additional financing was required; management was pursuing equity or debt financing and pharmaceutical licensing or co-development arrangements, with no assurance of success. Without funding or partnerships, the company said it may need to scale back plans or pause activities.
• The filing states that recurring losses, negative operating cash flows, demand-payable stockholder debt, and the financing need raise substantial doubt about the company’s ability to continue as a going concern. The financial statements include no adjustments for a possible failure to continue as a going concern.
• Development, regulatory approval, commercialization, competition, and market acceptance are material uncertainties. Phase 3 activity and other development plans depend on available financing. The company reported no material pending legal claims and said disclosure controls were effective at a reasonable-assurance level.

Key facts investors should verify

• Confirm that the Oncobiologics filing is the intended filing for the requested Outlook Therapeutics entity and reporting period.
• Verify the company’s post-quarter cash, financing, and actual operating runway, given the stated February 2017 funding horizon.
• Review the senior-note terms, secured collateral, maturity and repayment capacity, as well as the $4.6 million of stockholder notes payable on demand.
• Track whether licensing or co-development transactions closed and whether they provided meaningful cash or changed development ownership or economics.
• Confirm the funding, timing, and regulatory status of Phase 3 plans for ONS-3010 and ONS-1045, and assess the basis for future revenue assumptions.